Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie (NYSE: ABBV) is set to participate in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 2:45 p.m. CT. Key executives, including Robert A. Michael, Michael E. Severino, M.D., and Jeffrey R. Stewart, will present virtually. A live audio webcast will be accessible on AbbVie's Investor Relations website, with an archived session available later that day. AbbVie focuses on innovative medicines across various therapeutic areas including immunology and oncology.
On December 16, 2021, Allergan Aesthetics, part of AbbVie (NYSE: ABBV), completed its acquisition of Soliton, Inc. (NASDAQ: SOLY). This acquisition enhances Allergan's offering of non-invasive body contouring solutions by adding the RESONIC™ device, which is FDA-cleared for long-term cellulite improvement and tattoo removal. Clinical data showed that 97.6% of participants reported significant cellulite improvement post-treatment. The acquisition reflects Allergan's commitment to innovation in aesthetic treatments, addressing consumer concerns about cellulite.
AbbVie announced the FDA's approval of RINVOQ (upadacitinib) for treating adults with active psoriatic arthritis (PsA) who are unresponsive or intolerant to TNF blockers. This approval is backed by two Phase 3 trials, SELECT-PsA 1 and SELECT-PsA 2, where RINVOQ met its primary endpoint with ACR20 responses of 71% and 57% vs. placebo. It demonstrated significant improvements in joint efficacy, physical function, and fatigue. Despite its benefits, RINVOQ carries risks of serious infections and cardiovascular events, particularly in older patients with heart disease risk factors.
Allergan, part of AbbVie, announced the availability of VUITY™ (pilocarpine HCl ophthalmic solution) 1.25%, the first FDA-approved eye drop for treating presbyopia, affecting around 128 million Americans. The innovative formulation utilizes proprietary pHast™ technology to enhance near vision while maintaining distance focus. Clinical studies demonstrated significant efficacy, with participants achieving notable improvements in visual acuity.
VUITY is now available by prescription in pharmacies across the U.S., emphasizing AbbVie's commitment to advancing eye care.
AbbVie announced promising top-line results from the Phase 3 U-EXCEED study of upadacitinib for moderate to severe Crohn's disease. At week 12, 39% of patients achieved clinical remission via CDAI, and 40% showed remission via SF/AP, significantly outperforming the placebo (21% and 14%, respectively; p0.0001). Endoscopic response was seen in 35% of the upadacitinib group versus 4% in placebo (p<0.0001). The safety profile remains consistent with previous studies, with common adverse events predominantly mild. Full data will be presented at medical conferences soon.
AbbVie has updated the U.S. prescribing information for RINVOQ (upadacitinib) for moderate to severe rheumatoid arthritis (RA) treatment. This follows an FDA Drug Safety Communication on Sept. 1, 2021, which flagged risks like malignancy and major adverse cardiac events (MACE) associated with JAK inhibitors. The updated label now emphasizes these risks in the warnings section. RINVOQ is now indicated for patients with an inadequate response or intolerance to TNF blockers. The FDA is also reviewing supplemental applications for RINVOQ for several additional conditions.
AbbVie has submitted an application to the European Medicines Agency (EMA) for risankizumab (SKYRIZI) as a treatment for moderate to severe active Crohn's disease in patients aged 16 and older. This application is based on results from three pivotal Phase 3 studies: ADVANCE, MOTIVATE, and FORTIFY, which demonstrated significant improvements in clinical remission and endoscopic response. No new safety risks were identified compared to the existing safety profile. Approval is still pending, and risankizumab's use for Crohn's disease has not yet been established by regulatory authorities.
AbbVie (NYSE: ABBV) will participate in the 4th Annual Evercore ISI Virtual HealthCONx Conference on December 2, 2021, at 11:10 a.m. CT. Key executives, including Michael Severino, Robert A. Michael, and Jeffrey R. Stewart, will present. A live audio webcast will be available on AbbVie’s Investor Relations website, with an archived edition accessible later that day. AbbVie aims to discover innovative medicines to address serious health issues across various therapeutic areas, including immunology and oncology.
AbbVie (NYSE: ABBV) will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1, 2021, at 9:30 a.m. CT. Key executives, including Michael Severino, Robert A. Michael, and Jeffrey R. Stewart, will present during the event. The presentation can be accessed via a live audio webcast on AbbVie's Investor Relations website, with an archived version available later that day. AbbVie is dedicated to discovering innovative treatments across various therapeutic areas, including immunology, oncology, and neuroscience.
On November 19, 2021, AbbVie announced that its Allergan Aesthetics division will present six abstracts at the virtual American Society for Dermatologic Surgery meeting from November 19-21. The presentations will highlight innovative findings on aesthetic treatments, particularly featuring BOTOX® Cosmetic. Two abstracts received recognition as 'Best of Cosmetic Oral Abstracts.' One of the sessions, led by Dr. Arisa Ortiz, will showcase the SkinMedica® TNS® Advanced+ Serum's efficacy in enhancing skin appearance. This meeting reinforces Allergan's commitment to advancing aesthetic medicine.